Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03198078 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 316
- Enrollment target
NCT03198078 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 316 participants.
The verdict
NCT03198078, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 316 participants
- Enrollment target
Study Summary
To determine the safety \& efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.
Interventions
- DRUG Placebo
- DRUG Aripiprazole
- DRUG Brexpiprazole (OPC-34712)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2017-06-30 |
| Est. Completion | 2023-04-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03198078
The ClinicalTrials.gov registry entry for NCT03198078 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03198078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03198078 about?
NCT03198078 is a clinical study titled "Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia". To determine the safety \& efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.
What is the current status of trial NCT03198078?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 316 participants. The study started on 2017-06-30. Estimated completion is 2023-04-03.
What interventions are being tested in trial NCT03198078?
The interventions under investigation include: Placebo (DRUG), Aripiprazole (DRUG), Brexpiprazole (OPC-34712) (DRUG).
Who is sponsoring clinical trial NCT03198078?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.